XuXiang Chen

Dr. XuXiang Chen


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HDHua Dai
Hua Dai
XTXin Tao
Xin Tao
YSYuansen Shu
Yuansen Shu
FLFanrong Liu
Fanrong Liu
XCXiaoping Cheng
Xiaoping Cheng
ZCZhaorui Cheng
Zhaorui Cheng
Hepatocellular carcinoma (HCC) is a predominant cause of cancer-related mortality globally, noted for its propensity towards late-stage diagnosis and scarcity of effective treatment modalities. The process of metabolic reprogramming, with a specific emphasis on lipid metabolism, is instrumental in the progression of HCC. Nevertheless, the precise mechanisms through which lipid metabolism impacts HCC and its viability as a therapeutic target have yet to be fully elucidated. In the current investigation, single-cell RNA sequencing in conjunction with weighted gene co-expression network analysis (WGCNA) was utilized to delineate lipid metabolism-related genes correlated with the prognostic outcomes of hepatocellular carcinoma (HCC). Data procurement encompassed transcriptomic and clinical datasets from HCC patients, sourced from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) repositories. Subsequent to this, consensus clustering analysis was implemented to stratify patients into distinct subgroups, contingent upon the expression patterns of lipid metabolism genes. Further analytical procedures involved functional enrichment analysis, evaluation of immune infiltration, and examination of the mutation landscape.PTGES3 was identified as a pivotal gene associated with lipid metabolism. Subsequent to its identification, cellular communication analysis was employed to assess the immunological attributes of PTGES3 within the tumor microenvironment. The functional role of PTGES3 was further corroborated through molecular docking simulations and in vitro experimental assays. We identified 27 genes associated with lipid metabolism, 18 of which exhibited significant correlation with overall survival in HCC patients. PTGES3 emerged as a central gene, demonstrating a robust association with immune cell infiltration and unfavorable prognosis. Cellular communication analysis revealed that PTGES3 exhibits the highest communication intensity with T cells, modulating the tumor microenvironment by potentiating the FN1/CD44 + MDK/NCL signaling pathway. Elevated expression of PTGES3 was linked to immunosuppressive cascades, diminished responsiveness to immunotherapy, and inferior overall survival outcomes. Molecular docking analysis indicated that etoposide, methotrexate, and doxorubicin could effectively bind to PTGES3. In vitro experiments confirmed that PTGES3 knockdown significantly impaired the proliferation, invasion, and migration of HCC cells. This study highlights the pivotal role of lipid metabolism in HCC progression and identifies PTGES3 as a potential prognostic biomarker and therapeutic target. These findings offer new insights into the development of targeted therapies for HCC, particularly in patients with high PTGES3 expression.

27 October 2025 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
LZLi Zong
Li Zong
PCPei Chen
Pei Chen
JSJing Shi
Jing Shi
HCHuijie Chen
Huijie Chen
WLWen-wen Lin
Wen-wen Lin
XCXuXiang Chen
XuXiang Chen
Viral encephalitis, characterized by inflammation of the brain parenchyma, poses a significant threat to public health due to its high rates of morbidity and mortality. Microglia, the central nervous system’s resident immune cells, are crucial in the pathophysiology and development of this condition. These microglia exhibit a dual function, being involved in both neuroprotection and neurotoxicity during viral encephalitis. To address this complex interplay, targeted therapeutic strategies that modulate microglia activation state have emerged as a promising approach. These strategies aim to either inhibit excessive microglia activation or promote their neuroprotective functions. By targeting microglia, these therapies hold the potential to improve outcomes for patients with viral encephalitis. This review synthesizes current evidence revealing that microglial responses during viral encephalitis exhibit context-dependent heterogeneity that extends beyond traditional M1/M2 paradigms. Critically, our review reveals a significant translational gap, with no current clinical trials investigating microglial-targeted therapies for viral encephalitis despite promising preclinical evidence. This review provides a comprehensive framework for understanding microglial complexity in viral encephalitis and establishes research priorities for advancing these insights toward clinical application.

26 November 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CZChao Zhong
Chao Zhong
ZCZhaorui Cheng
Zhaorui Cheng
YSYuansen Shu
Yuansen Shu
XYXiaojuan Yang
Xiaojuan Yang
JHJia Hu
Jia Hu
YLYun Liu
Yun Liu
Background Colorectal cancer (CRC) stands as the most common gastrointestinal malignancy, with the Follistatin-like 1 (FSTL1) gene associated with unfavorable outcomes in diverse cancer forms. Nonetheless, the precise mechanisms through which FSTL1 influences CRC pathogenesis and its associated multi-omics characteristics remain unclear. Methods This study leveraged RNA sequencing and single-cell RNA sequencing (scRNAseq) data from the Gene Expression Omnibus (GEO) database to scrutinize the expression profile, prognostic significance, and clinicopathological relevance of FSTL1 in colorectal cancer. Gene set enrichment analysis (GSEA) and protein-protein interaction (PPI) network analysis were conducted to delve into the potential biological functions of FSTL1 in colorectal cancer and its associated pathways. The ESTIM algorithm and Tumor Immune Estimation Resource (TIDE) database were utilized to investigate FSTL1 expression in immune cell infiltration and immune checkpoints. Mutation characteristics of FSTL1 were elucidated using the cBioPortal database. The pRRophetic package was employed to identify potential chemotherapeutic drugs targeting FSTL1. Expression levels of FSTL1 in colon cancer and adjacent normal tissues were evaluated using the Human Protein Atlas (HPA) database. Furthermore, single-cell sequencing technology and cell communication were employed to assess the immunogenomic features of FSTL1 in the tumor microenvironment. In vitro experiments were conducted to validate the efficacy of FSTL1. Results FSTL1 levels were markedly higher in colorectal cancer tissues compared to healthy tissues, correlating significantly with unfavorable patient outcomes. Elevated FSTL1 expression was closely linked to key biological processes including the PI3K pathway, cell adhesion, proliferation, migration, and extracellular matrix remodeling. Furthermore, FSTL1 expression exhibited strong associations with immune cell levels and the tumor immune microenvironment in colorectal cancer. Notably, FSTL1 mutations predominantly comprised missense mutations and displayed significant correlations with various immune checkpoints and low methylation levels. Axitinib emerged as a promising targeted therapeutic option for patients with high FSTL1 expression. Analysis from the HPA database confirmed elevated FSTL1 expression in colorectal tissues compared to adjacent normal tissues. Single-cell sequencing analysis identified stromal cells as the primary source of abundant FSTL1 expression, potentially influencing tumor microenvironment remodeling by myeloid and B cells via the APP-CD74 pathway. Downregulating FSTL1 expression in colon cancer cells suppresses the proliferation, motility, and invasiveness of SW480 and HCT116 colon cancer cells. Conclusion In summary, the findings of the study indicate that elevated FSTL1 expression could serve as a prognostic biomarker for unfavorable outcomes in colorectal cancer (CRC) diagnosis and may also identify potential targets for immunotherapy in CRC.

26 June 2026 in PLOS ONE
Verified
Journal Article
Open access
BWBiao Wang
Biao Wang
YAYangfang An
Yangfang An
YSYuansen Shu
Yuansen Shu
XCXiaoping Cheng
Xiaoping Cheng
XCXuXiang Chen
XuXiang Chen
ZCZhaorui Cheng
Zhaorui Cheng
Objective: Glioblastoma (GBM) is the most aggressive type of intracranial malignant tumor, known for its extremely poor prognosis. Lactylation, a newly identified post-translational modification, has been linked to tumorigenesis, though its specific role in GBM remains unclear. This study aims to integrate single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) data to create a novel prognostic model for GBM, focusing on lactylation-related factors. Methods: We studied lactate metabolism genes as markers in GBM. We obtained bulk transcriptomic data from TCGA and the GSE141383 and GSE162631 cohorts in the GEO databases. We used the R package Seurat to analyze scRNA-seq data, CellChat for cell communication analysis, and AUCell to assess lactate metabolism gene set scores across cell types. We developed a prognostic model using machine learning algorithms and tested its efficacy across multiple cohorts. Additionally, we investigated differences in immune infiltration, predicted sensitivity, and other factors between high and low-risk groups. We validated the function of the key gene CD93 at the cellular level. Results: The scRNA-seq data identified nine major cell types in GBM, with FCGBP+ macrophages showing the highest score in the lactate metabolism gene set. Authors designed a model informed by machine learning pinpointed three key genes(CD93, FCER1G, and GRB2)and developed a model with optimal prognostic value across cohorts.The high-risk group presented significantly poorer clinical outcomes. Immune-related bioinformatic analysis revealed significant differences in immune cell infiltration and checkpoint gene expression between risk groups. High-risk patients demonstrated lower immune infiltration and higher immunosuppression, rendering them less suitable for immunotherapy. Predictive algorithms indicated that axitinib and imatinib could be potential therapeutic drugs for these high-risk patients. In GBM tissue and cells, CD93 expression was significantly elevated, identifying it as a key risk gene in this model. Inhibition of CD93 expression via siRNA significantly reduced the proliferation, invasion, and migration of U87 and U251 cells. Conclusion: In summary, we developed a novel characterization of lactylation-related clusters using single-cell sequencing technology. This study provided insights into the prognostic significance of lactate metabolism-related genes in GBM.